Physician profile
Mark B Schenkel
NPI 1104863216
$5,151.46
in general payments reported to CMS, 2019-2025
21 companies · $978 in 2025
The $978 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $350 · 2021: $597 · 2022: $657 · 2023: $865 · 2024: $426 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,474.53 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $509.62 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.50 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Biohaven Pharmaceuticals, INC. | $371.36 | 2021 | |
| Pfizer INC. | $328.40 | 2021-2025 | |
| Allergan, INC. | $260.96 | 2019-2020 | |
| Amgen INC. | $243.76 | 2023 | Otezla, Repatha |
| Abbvie INC. | $169.98 | 2024-2025 | |
| Novo Nordisk INC | $166.67 | 2021-2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $161.68 | 2022-2025 | Eterna, Freestyle Libre 2 |
| Silk Road Medical, INC. | $147.15 | 2019 | |
| Dexcom, INC. | $137.66 | 2023 | Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $125.83 | 2019 | |
| Exact Sciences Corporation | $122.07 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $115.29 | 2025 | Intracept |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $106.35 | 2022 | |
| Lilly USA, LLC | $68.43 | 2020-2025 | Zepbound, Jardiance |
| Grt US Holding, INC. | $54.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $51.71 | 2023 | Evkeeza |
| Sanofi Pasteur INC. | $28.46 | 2019 | |
| Lundbeck LLC | $26.28 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schenkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.